Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $322.75 +5.42 (+1.71%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$322.02 -0.73 (-0.22%) As of 10/30/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ligand Pharmaceuticals Stock (NASDAQ:LGND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ligand Pharmaceuticals alerts:Sign Up Key Stats Today's Range$314.51▼$324.9050-Day Range$275.20▼$322.7552-Week Range$175.89▼$326.63Volume344,299 shsAverage Volume226,438 shsMarket Capitalization$6.44 billionP/E Ratio144.08Dividend YieldN/APrice Target$339.22Consensus RatingBuy Company Overview Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company that develops, acquires and licenses technologies intended to improve the development and commercialization of medicines. Rather than operating primarily as a traditional drug manufacturer, Ligand generally works with pharmaceutical and biotechnology partners, receiving licensing payments, royalties and other consideration tied to partnered products. The company’s principal technology is Captisol, a modified cyclodextrin designed to improve the solubility, stability and delivery of certain active pharmaceutical ingredients. Captisol is used in several approved medicines developed by partners, including products in oncology and other therapeutic areas. Ligand also has interests in a portfolio of proprietary drug-development programs and other enabling technologies spanning areas such as cancer, infectious diseases, immunology and rare diseases. Founded in 1987, Ligand has built its business through internal research, acquisitions and licensing agreements with pharmaceutical companies and biotechnology firms. Its technologies and partnered products serve international markets through licensees and commercial partners, giving the company a global presence without relying solely on its own sales infrastructure.AI Generated. May Contain Errors. Read More Ligand Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreLGND MarketRank™: 3.097790560855 of 5 starsLigand Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 345th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingBuy Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Ligand Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLigand Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ligand Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth59.05% Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 59.05% in the coming year, from $5.25 to $8.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 144.08, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 144.08, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.68.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 2.58. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.29% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 10.53, which indicates bearish sentiment.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 6.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.82 News SentimentLigand Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Ligand Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,068,898.00 in company stock.Percentage Held by Insiders5.60% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LGND Stock News HeadlinesLigand Pharmaceuticals (LGND) Stock Price Ignores Q3 Earnings Losses And Royalty StrengthOctober 30 at 5:50 PM | finance.yahoo.comLigand Pharmaceuticals Incorporated 2026 Q3 - Results - Earnings Call PresentationOctober 30 at 11:31 AM | seekingalpha.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.October 31 at 1:00 AM | Behind the Markets (Ad)Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call TranscriptOctober 30 at 2:00 AM | seekingalpha.comLigand Pharmaceuticals Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 29 at 11:46 AM | marketscreener.comMEarnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $2.67 per Share, vs. FactSet Est of $2.33October 29 at 11:46 AM | marketscreener.comMLigand Reports Third Quarter 2026 Financial ResultsOctober 29 at 7:00 AM | globenewswire.comLigand to Participate in November Investor ConferencesOctober 27, 2026 | globenewswire.comSee More Headlines LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $189.07 at the beginning of the year. Since then, LGND stock has increased by 70.7% and is now trading at $322.75. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings results on Thursday, October, 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.34. Ligand Pharmaceuticals's quarterly revenue was down 31.8% on a year-over-year basis. Read the conference call transcript. Who are Ligand Pharmaceuticals' major shareholders? Top institutional investors of Ligand Pharmaceuticals include Congress Asset Management Co. (3.30%), Moody Aldrich Partners LLC (0.10%), Woodstock Corp (0.09%) and Isthmus Partners LLC (0.08%). Insiders that own company stock include Todd C Davis, Matthew E Korenberg, John W Kozarich, Stephen L Sabba, Andrew Reardon, Octavio Espinoza, John L Lamattina, Nancy Ryan Gray, Jason Haas and Martine Zimmermann. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Block (XYZ) and Palo Alto Networks (PANW). Company Calendar Last Earnings10/29/2026Today10/31/2026Investor Day 202612/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LGND's financial health is in the Green zone, according to TradeSmith. LGND has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees47Year Founded1987Price Target and Rating Average Price Target for Ligand Pharmaceuticals$339.22 High Price Target$397.00 Low Price Target$220.00 Potential Upside/Downside+5.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$2.24 Trailing P/E Ratio144.08 Forward P/E Ratio61.48 P/E Growth2.58Net Income$124.45 million Net Margins20.27% Pretax Margin20.77% Return on Equity5.22% Return on Assets2.74% Debt Debt-to-Equity Ratio1.17 Current Ratio13.35 Quick Ratio30.96 Sales & Book Value Annual Sales$268.09 million Price / Sales24.01 Cash Flow$7.85 per share Price / Cash Flow41.10 Book Value$48.24 per share Price / Book6.69Miscellaneous Outstanding Shares19,940,000Free Float18,820,000Market Cap$6.44 billion OptionableOptionable Beta1.14 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:LGND) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
